Our Take
Three vendor presentations at a medical conference is news, not progress—until you know what the data actually showed.
Why it matters
Diabetes device makers use ADA's annual Scientific Sessions to validate product performance and influence clinical adoption. These presentations shape which systems doctors recommend and which insurers cover.
Do this week
Clinicians and payers: request full abstracts or published results from Tandem, Insulet, and Dexcom before updating formularies or device protocols.
Three major players presented at ADA Scientific Sessions
Tandem Diabetes Care, Insulet, and Dexcom all presented data over the weekend at the American Diabetes Association's Scientific Sessions. The source does not specify what data was presented, the magnitude of any findings, or whether results were peer-reviewed or vendor-only benchmarks.
Conference presentations alone don't prove clinical value
ADA Scientific Sessions attract clinicians, researchers, and industry. Presentations generate visibility and often precede journal publication. However, conference talks and posters are not independently verified—they reflect what companies choose to show. Without access to the actual abstracts or results, it is impossible to assess whether these presentations report meaningful clinical advances, incremental tweaks to existing products, or positioning statements ahead of product launches.
For practitioners evaluating these companies' devices, the difference matters. A statistically significant improvement in glucose control accuracy or reduction in severe hypoglycemic events should inform device selection. A marketing-flavored presentation of already-known capabilities should not.
Don't act on conference announcements alone
Request copies of the formal abstracts and any published results before recommending devices or updating clinical protocols. If results are not yet published or available on company websites, ask when peer review is expected. Conference presentations often preview findings that will appear in journals weeks or months later, and the published version frequently contains caveats, competing-interest disclosures, and sample-size limitations that the live talk may downplay.
Tandem, Insulet, and Dexcom are serious manufacturers with substantial market share. Their data is worth evaluating. But evaluation requires the data itself, not just the announcement that data exists.